ZOLL, an Asahi Kasei company, announced that its Zenix monitor/defibrillator has received premarket approval (PMA) from the U.S. Food and Drug Administration, marking a significant advancement in emergency care technology. The device represents the company's most clinically advanced and user-friendly professional monitor/defibrillator designed for both EMS and hospital environments.
Advanced Technology for Critical Care
The Zenix monitor/defibrillator incorporates ZOLL's innovative Real BVM Help and exclusive Real CPR Help technology, providing healthcare providers with real-time clinical feedback to improve ventilation quality and deliver high-quality CPR. This advanced technology empowers EMS teams and hospital clinicians to make informed, confident decisions while ensuring exceptional patient care delivery.
Built from years of customer feedback, the device combines intuitive design with powerful functionality to enhance patient care and automate workflows. The monitor/defibrillator features a large, durable touchscreen that provides critical information when needed, with on-the-fly customization capabilities allowing healthcare professionals to make real-time adjustments during high-pressure situations.
User-Centric Design and Functionality
"Whether you are a hospital clinician or an EMS professional, the ZOLL Zenix monitor/defibrillator is designed to work the way you work," said Elijah White, President of ZOLL Acute Care Technology. "Zenix is our most advanced monitor/defibrillator, and yet it's incredibly easy to use—virtually all functions of the device are accessible with three screen-touches or less."
The device's design prioritizes efficiency, clarity, and intelligence, redefining how emergency care equipment operates in critical situations. White emphasized that along with the X Series and R Series, Zenix extends ZOLL's leadership in professional monitors/defibrillators with unique features and intuitive design.
Market Availability and Company Background
The Zenix monitor/defibrillator is now available to customers in the U.S. and Canada. ZOLL develops and markets medical devices and software solutions that advance emergency care and save lives while increasing clinical and operational efficiencies. The company provides a comprehensive set of technologies including products for defibrillation and cardiac monitoring, circulation enhancement and CPR feedback, supersaturated oxygen therapy, data management, ventilation, therapeutic temperature management, and sleep apnea diagnosis and treatment.
As part of the Asahi Kasei Group, which employs more than 50,000 people worldwide, ZOLL operates within a company that contributes to sustainable society solutions through three business sectors: Healthcare, Homes, and Material. Asahi Kasei's healthcare operations encompass devices and systems for critical care, products and services for biotherapeutics manufacture, and a growing portfolio of specialty pharmaceuticals.
